Status: Currently Official on 14-Feb-2025
Official Date: Official as of 01-May-2018
Document Type: USP Monographs
DocId: GUID-52820740-1FB8-47C6-B6EF-361F98AFCEDA_3_en-US
DOI: https://doi.org/10.31003/USPNF_M11350_03_01
DOI Ref: eel2p

© 2025 USPC Do not distribute

Calcitonin Salmon Injection

DEFINITION

Calcitonin Salmon Injection is a sterile solution of Calcitonin Salmon in a suitable diluent. Each mL of Calcitonin Salmon Injection possesses an activity of NLT 80% and NMT 120% of that stated on the label.

IDENTIFICATION

• A. The retention time of the major peak of the Sample solution corresponds to that of the Standard solution, as obtained in the Assay.

ASSAY

PROCEDURE

Solution A: Dissolve 3.26 g of tetramethylammonium hydroxide pentahydrate in 900 mL of water, add 100 mL of acetonitrile, and mix. Adjust with phosphoric acid to a pH of 2.5, pass through a filter of 0.5-µm or finer pore size, and degas.

Solution B: Dissolve 1.45 g of tetramethylammonium hydroxide pentahydrate in 400 mL of water, add 600 mL of acetonitrile, and mix. Adjust with phosphoric acid to a pH of 2.5, pass through a filter of 0.5-µm or finer pore size, and degas.

Mobile phase: See <u>Table 1</u>.

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	72	28
30	48	52
32	72	28
55	72	28

System suitability solution: Prepare a solution in *Solution A* containing about 0.2 mg/mL of <u>USP Calcitonin Salmon Related Compound A RS</u> and 0.2 mg/mL of <u>USP Calcitonin Salmon RS</u>. Take 0.1 mL of this solution, add 0.9 mL of *Solution A*, and mix.

Standard stock solution: 1.0 mg/mL of USP Calcitonin Salmon RS in Solution A

Standard solution: 0.1 mg/mL of USP Calcitonin Salmon RS from Standard stock solution diluted with Solution A

Sample solution: Use the solution from an undiluted Injection vial.

Chromatographic system

(See Chromatography (621), System Suitability.)

Mode: LC

Detector: UV 220 nm

Column: 4.6-mm × 25-cm; packing L1

Column temperature: 65° Flow rate: 1 mL/min Injection volume: 200 μ L

System suitability

Sample: System suitability solution

[Note—The relative retention times for calcitonin salmon and calcitonin salmon related compound A are 1.0 and 1.15, respectively.]

Suitability requirements

Resolution: NLT 3 between calcitonin salmon and calcitonin salmon related compound A

Tailing factor: NMT 2.5

Relative standard deviation: NMT 3%

Analysis

Samples: Standard solution and Sample solution

Calculate the potency, in USP Calcitonin Salmon Units/mL, in the portion of Injection taken:

= peak area from the Sample solution

r_s = peak area from the Standard solution

 $C_{
m c}=$ concentration of <u>USP Calcitonin Salmon RS</u> in the *Standard solution* (USP Calcitonin Salmon Units/mL)

Acceptance criteria: 80%-120%

SPECIFIC TESTS

- BACTERIAL ENDOTOXINS TEST (85): NMT 0.625 USP Endotoxin Units/USP Calcitonin Salmon Unit
- Sterility Tests (71): Meets the requirements when tested as directed in Test for Sterility of the Product to Be Examined, Membrane Filtration
- Particulate Matter in Injections (788): Meets the requirements for small-volume injections
- PH (791): 3.9-4.5
- INJECTIONS AND IMPLANTED DRUG PRODUCTS (1): Meets the requirements

ADDITIONAL REQUIREMENTS

- PACKAGING AND STORAGE: Preserve in single-dose or multiple-dose containers, preferably of Type I glass. Avoid freezing. Store in a refrigerator.
- LABELING: Label it to indicate the activity in USP Calcitonin Salmon Units/mL. The labeling states that the material is synthetic. Label it to state that it is to be stored in a refrigerator, and that freezing is to be avoided.
- USP REFERENCE STANDARDS (11)

USP Calcitonin Salmon RS

USP Calcitonin Salmon Related Compound A RS

N-Acetyl-cys¹-calcitonin.

 $C_{146}H_{243}N_{44}O_{49}S_2$

Auxiliary Information - Please check for your question in the FAQs before contacting USP.

3463

Topic/Question	Contact	Expert Committee
CALCITONIN SALMON INJECTION	Ying Han Associate Science & Standards Liaison	BIO12020 Biologics Monographs 1 - Peptides

Chromatographic Database Information: Chromatographic Database

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 40(4)

Current DocID: GUID-52820740-1FB8-47C6-B6EF-361F98AFCEDA_3_en-US Previous DocID: GUID-52820740-1FB8-47C6-B6EF-361F98AFCEDA_1_en-US

DOI: https://doi.org/10.31003/USPNF_M11350_03_01

DOI ref: eel2p